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Background: We sought to determine the prevalence of drug resistant TB among outpatients initiating TB treat-
ment in Lilongwe, Malawi.
Methods: This was a prospective cohort study of patients 18 years and older initiating TB treatment at Martin
Preuss Centre, the primary integrated HIV/TB clinic in Lilongwe, Malawi, from April 2011 to July 2012.
Procedures included questionnaires, physical exam, chest x-ray, full blood count and sputum collection.
Sputum samples underwent acid-fast bacilli (AFB) smear testing and culture by Lowenstein-Jensen (LJ) and
liquid Mycobacteria Growth Indicator Tube (MGIT) methods. Drug sensitivity was investigated using the Hain
GenoType MTBDRplus line probe assay.
Results: Of the 702 patients, 219 (31.2%) were female and 653 (93.0%) were presenting for first-time TB treat-
ment. HIV co-infection was present in 420 (59.8%) cases, with 137 (32.6%) of those patients receiving antiretro-
viral therapy at presentation. TB was culture-confirmed in 375 (53.4%) patients, 349 of which were first time
treatment and 26 retreatment. Ten cases of isoniazid-resistant TB (2.9% of culture confirmed cases of newly trea-
ted TB), one of rifampin-resistant TB (0.3% culture confirmed cases of newly treated TB) and one of multi-drug
resistant TB (MDR-TB) (3.8% of culture confirmed cases of retreatment TB) were detected.
Conclusions: MDR-TB prevalence is low among outpatients initiating TB treatment in Lilongwe.
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Introduction
Despite efforts to control the spread of TB in Africa, there are
2.3 million new cases that lead to a quarter million deaths annually.1
To further complicate this situation, Africa is currently experiencing a
nearly 6% annual increase in cases of multi-drug resistant TB
(MDR-TB), the fastest of any WHO region. Given that most countries
in Sub-Saharan Africa have limited laboratory capacity and public
health care infrastructure, resources which are already under signifi-
cant strain from the longstanding HIV epidemic, the region has
become a potentially fertile breeding ground for MDR-TB. Despite
this concern, data on drug resistance in Sub-Saharan Africa is scarce
outside of South Africa, which has a more advanced public health
care system than its surrounding countries.
Malawi, a country of 14 million people, has been struck hard by
both HIV and TB. Despite successful expansion of the antiretroviral
therapy programme with marked reductions in HIV mortality and
prevalence2 HIV prevalence remains high at 10.6%, and 68% of TB
cases are HIV co-infected.3 Meanwhile, MDR-TB remains a concern
for this vulnerable population. The WHO estimates that there were
up to 990 cases of MDR-TB in Malawi in 2009, though only six of
those cases were identified and enrolled in treatment.4
Previous studies of drug resistant TB in Malawi have focused on
inpatients being treated for TB5 or only patients undergoing treat-
ment for recurrent smear positive pulmonary TB.6 However, inpa-
tients make up only a small portion of the total population of
those with TB, and smear negative pulmonary TB is common
among HIV co-infected patients.7 Given the significant numbers
of TB patients who are treated as outpatients and the high burden
of HIV/TB co-infection, a broader investigation of drug resistance
in Malawian patients living with TB is needed. In this study we
evaluate the prevalence of drug resistant TB in Lilongwe,
Malawi, among outpatients with new and retreatment TB, as
well as smear positive and smear negative TB.
# The Author 2015. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved.

















In Malawi all patients diagnosed with TB are registered for treat-
ment at TB clinics. Martin Preuss Centre, located on the campus of
Bwaila Hospital, serves as Lilongwe’s primary integrated HIV/TB
treatment clinic and contains Malawi’s largest TB registry.
Patients arrive by two different routes, one being referral from sur-
rounding facilities for commencement of treatment once they
have been diagnosed with TB and the other being self-referral
for sputum submission for those who have experienced chronic
cough, defined as cough lasting longer than 3 weeks.
Study design and population
This was a prospective observational cohort study including all
adult (age 18 years and older) patients registering for TB treat-
ment at Martin Preuss Centre from April 2011 to July 2012.
Originally, only patients presenting for TB treatment for the first
time were enrolled. However, in November 2011 the study proto-
col was amended to allow for the additional enrollment of
patients who had previously defaulted (been lost to follow-up),
experienced treatment failure or whose TB had relapsed.
Exclusion criteria included being less than 18 years of age, being
a prisoner, or already being on TB treatment initiated at another
facility. Once registered, patients were treated according to the
Malawi National Tuberculosis Control Programme manual,8 with
first-treatment patients receiving isoniazid, rifampicin, pyrazina-
mide and ethambutol, and retreatment patients receiving strep-
tomycin, isoniazid, rifampicin, pyrazinamide and ethambutol.
Those with MDR-TB were admitted to the hospital and received
capreomycin, levofloxacin, ethionamide, cycloserine and pyrazi-
namide for 6 months, followed by 18 months of levofloxacin,
ethionamide, and cycloserine at home through a community
based approach.
Enrollment procedures
Study personnel obtained written informed consent from each
patient and administered a questionnaire that covered demo-
graphics, past medical history, symptoms, and diagnostic details
(acid-fast bacilli [AFB] smear status and radiographic details). We
collected blood for full blood count, sputum samples, and per-
formed a chest x-ray on each patient. We offered rapid HIV testing
and counseling to patients with an unknown HIV status at the
time of enrollment. HIV infected individuals received a CD4
count and, if on antiretroviral therapy for greater than one year,
a plasma HIV RNA test. Highly active antiretroviral therapy was
initiated in those HIV infected individuals not yet on therapy,
according to Malawi’s national guidelines for the treatment
of HIV.9
Laboratory procedures
All specimens were analyzed at the University of North Carolina
Project laboratory, which has been given a four star ranking on
the WHO Stepwise Laboratory Improvement Process Towards
Accreditation (SLIPTA) Tier of Recognition by the African Society
for Laboratory Medicine.
Sputum samples were visualized microscopically after
auramine O staining and were considered to be smear positive
if bacilli were observed. Additionally, they were cultured on
Lowenstein-Jensen (LJ) and BACTECTM Mycobacteria Growth
Indicator Tube (MGIT; Becton, Dickinson and Company, Franklin
Lakes, NJ, USA). For culture-positive samples, the presence of
Mycobacterium tuberculosis complex (MTBC) was confirmed, and
rifampicin and isoniazid resistance determined, using the
GenoType MTBDRplus line probe assay (Hain Lifescience GmbH,
Nehren, Baden-Württemberg, Germany). If the presence of MTBC
was not confirmed using the GenoType MTBDRplus, samples were
tested with the Genotype Mycobacterium CM (Hain Lifescience
GmbH) to identify other strains of Mycobacterium. Drug suscepti-
bility testing is not included as part of Malawi’s standard of care.
Full blood count was performed using Beckman Coulter AcT
5diff Cap Pierce Hematology Analyzer, CD4 counts by BD
FACSCount System, and HIVRNA levels by Roche AMPLICOR
HIV-1 MONITOR Test version 1.5.
Statistical analysis
Data were double-entered into a Microsoft Access 2007 database
(Microsoft Corp., Redmond, WA, USA) and statistically analyzed
using Stata version 11.0 (Stata Corporation, College Station, TX,
USA). Standard x2, Fisher’s exact tests (two tailed) and t-tests
(two tailed, unpaired) were used to determine associations
between drug resistance and patient characteristics. A p,0.05
was considered statistically significant.
Ethical considerations
Study approval was obtained from the University of North Carolina
at Chapel Hill institutional review board and the Malawi National
Health Science Research Committee.
Results
Enrollment
Between April 2011 and July 2012, 2531 patients were registered
for TB treatment at Martin Preuss Centre. Of these, 1640 patients
were eligible to enroll in the study and 702 completed the enroll-
ment process. The most common reasons for ineligibility were the
patient not being physically present at registration (303), the
patient being retreated for TB (184) during the initial portion of
the study when retreatment patients were excluded, and the
patient being less than 18 years of age (174). Patients that were
ineligible for our study due to not being present at time of regis-
tration were admitted at local hospitals and were therefore not
part of the outpatient population under investigation. Of eligible
patients, the most common reasons for not joining were not
being asked to join the study due to staffing constraints (402),
being unable to produce a sputum sample (316) and reported
lack of time to participate in the study (120) (Figure 1).
Patient characteristics
The median age of study patients was 35 years old (range 19–80),
219 (31.2%) were female, and 653 (93.0%) were presenting with
TB for the first time (Table 1). Characteristics of both first time
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treatment patients and retreatment patients did not demonstrate
statistically significant differences, except for smear positivity of
sputum samples being more likely in retreatment patients
(p¼0.02). Pulmonary TB was the predominant form of TB, being
diagnosed in 614 (87.5%) cases. Abnormal findings on chest
x-ray were observed in 415 (59.1%) patients. HIV co-infection
was present in 420 (59.8%) cases, but only 137 (32.6%) of
those patients were receiving antiretroviral therapy at presenta-
tion, since most patients with HIV were diagnosed on the day of
enrollment in the study. Among HIV infected patients, those in the
retreatment group (p,0.001) and females (p¼0.02) were more
likely to be receiving antiretroviral therapy (Table 2). Of the 402 eli-
gible patients that were not asked to join the study, 380 (94.5%)
were receiving first time TB treatment, which was not statistically
different from the percentage of enrolled patients receiving first
time TB treatment (p¼0.66).
Laboratory findings
Of the 702 sputum samples collected from patients for laboratory
analysis, seven were inadequate in volume and one was lost, leav-
ing a total of 694 samples that were cultured for mycobacteria. Of
these 694 samples, AFB smear testing was positive in 244 (35.2%)
patients. Three hundred and seventy nine samples (54.6%) were
positive for mycobacteria by either LJ or MGIT culture. For MGIT
culture, four samples were discarded due to contamination and
three due to technical failure, leaving 687 MGIT cultured samples.
Of these, 368 samples were culture positive (53.6%). For LJ cul-
ture, 20 samples were discarded due to contamination and 25
were unculturable due to LJ medium being out of stock, leaving
649 LJ cultured samples. Of these, 333 samples were culture posi-
tive (51.3%).
Of the 379 samples that were either LJ or MGIT positive
for mycobacteria, testing by the Genotype Mycobacterium CM
demonstrated that three samples were positive for Mycobacterium
intracellulare and one for Mycobacterium avium. The remaining
375 culture positive samples were confirmed to be MTBC using the
GenoType MTBDRplus.
Both AFB and culture positivity differed according to HIV status.
AFB smear was positive in 116 of 420 (27.6%) HIV positive
patients versus 128 of 282 (45.4%) for HIV negative patients
(p,0.01). LJ or MGIT culture was positive for MBTC in 204 of 420
(48.6%) patients with HIV versus 171 of 282 (60.6%) of patients
without HIV (p,0.01) (Table 3). Of the 204 HIV positive patients
with culture confirmed mycobacteria, 89 (43.6%) had sputum
samples that were AFB smear negative.
The 375 MTBC culture positive samples were assessed for drug
resistance using the GenoType MTBDRplus line probe assay. Ten
cases (2.6%) of isoniazid mono-resistant TB were detected, all
from patients being treated for TB for the first time. All ten of
these cases were also positive by LJ and MGIT culture; how-
ever, three (30%) were AFB smear negative. Three hundred and
Figure 1. Study enrollment.
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forty nine of MTBC culture positive patients were being treated for
TB for the first time, while 26 were receiving re-treatment. This
resulted in a calculated prevalence of 2.9% (10/349) for isoniazid
mono-resistance in newly treated and culture confirmed cases of
MTBC. One case of rifampicin mono-resistant TB was detected,
from a patient being treated for TB for the first time. This case
was AFB smear positive and also positive by LJ and MGIT cultures,
resulting in a prevalence of 0.3% (1/349) in newly treated and cul-
ture confirmed cases of MTBC. One case of MDR-TB (resistant to
both isoniazid and rifampicin) was detected, originating from a
patient being retreated for TB. It was detected by LJ and MGIT cul-
tures, but was AFB smear negative, resulting in a prevalence of
3.8% (1/26) in retreatment culture confirmed cases of MTBC.
Table 1. Demographic and clinical characteristics of patients
Characteristic All patients (n¼702) First treatment (n¼659) Retreatment (n¼43) p-value
Median age with range (years) 35 (19–80) 34 (19–80) 37 (20–71) NS
Female 219 (31.2%) 203 (30.8%) 16 (37%) NS
Smear positive 244 (34.8%) 222 (33.7%) 22 (51%) 0.02
Pulmonary TB 614 (87.5%) 579 (87.9%) 35 (81%) NS
Extrapulmonary TB 88 (12.5%) 80 (12.1%) 8 (19%) NS
Meningitis (% EPTB) 1 (1%) 1 (1%) 0 NS
Lymphadenitis (% EPTB) 17 (19%) 16 (20%) 1 (13%) NS
Pericarditis (% EPTB) 10 (11%) 8 (10%) 2 (25%) NS
Pleuritis (% EPTB) 54 (61%) 49 (61%) 5 (63%) NS
Arthritis (% EPTB) 1 (1%) 1 (1%) 0 NS
Spinal (% EPTB) 2 (2%) 2 (3%) 0 NS
Miliarya (% EPTB) 8 (9%) 8 (10%) 0 NS
Abnormal CXRb 415 (59.1%) 392 (59.5%) 23 (53%) NS
Unilateral infiltrate (% Abnormal CXR) 156 (37.6%) 151 (38.5%) 5 (22%) NS
Bilateral infiltrate (% Abnormal CXR) 201 (48.4%) 188 (48.0%) 13 (57%) NS
Adenopathy (% Abnormal CXR) 69 (16.6%) 68 (17.3%) 1 (4%) NS
Miliary (% Abnormal CXR) 31 (7.5%) 30 (7.7%) 1 (4%) NS
Cavitary lesion (% Abnormal CXR) 96 (23.1%) 92 (23.5%) 4 (17%) NS
Pleural effusion (% Abnormal CXR) 68 (16.4%) 61 (15.6%) 7 (30%) NS
Pericardial effusion (% Abnormal CXR) 11 (2.7%) 10 (2.6%) 1 (4%) NS
HIV positive 420 (59.8%) 393 (59.6%) 27 (63%) NS
On ART (% of HIV+) 137 (32.6%) 121 (30.8%) 16 (59%) ,0.001
Median CD4 Count among positives (IQR) 167 (81–293) 160 (76–292) 185 (86–253) NS
VL suppressed to ,400 (% of HIV+on ART) (n¼53 VLs) 38 (72%) 33 (75%) 5 (56%) NS
ART: antiretroviral therapy; CXR: chest X-ray; EPTB: extrapulmonary TB; NS: not significant; VL: viral load.
a More than one Extrapulmonary category; b Total sums to .100% because patients often had more than one finding on CXR.
Table 2. Tests for association between patient characteristics in








37 (19–71) 36 (19–76) NS
Female 42 (30.7%) 30 (10.6%) 0.02
Smear positive 28 (20.4%) 27 (9.5%) NS
Pulmonary TB 82 (59.9%) 86 (30.4%) NS
Extrapulmonary TB 18 (13.1%) 14 (4.9%) NS
Abnormal CXR 63 (46.0%) 63 (22.3%) NS
Any resistance 3 (2.2%) 3 (1.1%) NS
ART: antiretroviral therapy; CXR: chest x-ray; NS: not significant.
Table 3. Acid-fast bacilli smear and Lowenstein-Jensen culture






AFB smear positive 116 (27.6%) 128 (45.4%) ,0.01
LJ or MGIT culture
positive
201 (47.9%) 171 (60.6%) ,0.01
AFB: acid-fast bacilli; LJ: Lowenstein-Jensen; MGIT: Mycobacteria
Growth Indicator Tube.
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Drug resistance was not associated with age, gender, TB treat-
ment status, TB site, AFB smear result, chest X-ray results or HIV
status (Table 4).
Discussion
Though others have reported low rates of MDR-TB in Malawi,5,6 our
study is one of the first to demonstrate that the presence of
MDR-TB in Malawi is very low among both first time and retreat-
ment outpatient cases, as well as among those who are sputum
positive or negative. This latter point is important as our study
confirmed a high rate of smear negative, LJ culture confirmed
TB (44%) among HIV co-infected patients, who represented
60% of our study population. Because TB is the leading cause of
death among HIV-infected persons,10 it is especially important to
understand the prevalence of MDR-TB in this population. Our
results are in line with a recently published nationally representative
cross sectional survey assessing drug resistant TB in Malawi con-
ducted from February 2010 to March 201111 that also demon-
strated low prevalence of MDR-TB (0.4% in new cases and 4.8%
retreatment cases), among patients with sputum smear positive TB.
Malawi currently appears to be faring better than some of
its neighboring countries in the MDR-TB epidemic, such as
Swaziland (prevalence of 0.9% of new cases and 9.1% of retreat-
ment cases), South Africa (prevalence of 1.8% of new cases and
6.7% of retreatment cases) and Mozambique (prevalence of 3.5%
of new cases and 11.2% of retreatment cases).4 This can be
partially attributed to the country’s well-managed national TB
control programme, which has used the directly observed treat-
ment short-course (DOTS) strategy since 1964.12 Treatment suc-
cess rates have continually improved, rising from 65% in 1995 to
88% in 2010,1 putting the country’s performance above the
WHO’s target of 85%. Though the importance of future evaluation
of prevalence in Malawi cannot be understated, our study
demonstrates that prevention of MDR-TB is possible, even in a
low resource country, through proper planning, implementation,
regular monitoring and evaluation of treatment administration.
The predominance of isoniazid mono-resistance in our study is
important due to the recent advent of the Xpert MTB/RIF assay,
which allows for the detection of both MTB and rifampicin resist-
ance simultaneously in less than two hours.13,14 The assay was
endorsed by the WHO in December 2010 and has since been spe-
cifically recommended as the initial diagnostic test in patients
with suspected drug resistant TB or HIV associated TB. As a result,
since June 2012, two-thirds of countries struggling with a high
prevalence of TB have included the assay in their national TB con-
trol programmes. However, due to the predominance of isoniazid
mono-resistance in our study results, the Xpert assay will under-
estimate overall TB drug resistance since it only detects rifampicin
resistance. Given the low prevalence of rifampicin resistance in
Malawi, the positive predictive value of the Xpert MTB/RIF assay
is low. Therefore cases of rifampicin resistance detected by this
assay should also be confirmed using drug susceptibility testing.15
The 3% prevalence of isoniazid resistance in patients being newly
treated for TB indicates a need for rapid detection of this mono-
resistance so that treatment regimens can be modified quickly to
prevent development of additional rifampicin resistance and sub-
sequent MDR-TB.
Prior studies have found associations between previous treat-
ment for TB, treatment not directly observed by a healthcare
worker and exposure to a known case of MDR-TB and the develop-
ment of MDR-TB.16,17 Associations have also been observed
between HIV co-infection and the development of MDR-TB; how-
ever, a recent meta-analysis of studies from Sub-Saharan Africa
revealed no association.16 We found no statistical associations
between patient characteristics and TB drug resistance.
However, our study was handicapped to show a statistical differ-
ence, given that there were so few drug resistant cases. Other lim-
itations of this study include the initial exclusion of patients
Table 4. Tests for association between patient characteristics and any type of drug resistance
Pansensitive (n¼363) Any drug resistancea (n¼12) p-value
Mean age (years) 34 36 NS
Female 106 (29.2%) 3 (25%) NS
First treatment 335 (92.3%) 11 (92%) NS
Retreatment 25 (6.9%) 1 (8%) NS
Abnormal X-ray (n¼155 and n¼7 x-rays) 147 (94.8%) 7 (100%) NS
Pulmonary TB 332 (91.5%) 11 (92%) NS
Extrapulmonary TB 28 (7.7%) 1 (8%) NS
Smear positive 234 (64.5%) 8 (67%) NS
HIV positive 195 (53.7%) 6 (50%) NS
Not on ART (% of HIV+) 130 (66.7%) 3 (50%) NS
Mean CD4 count among HIV+ 203 148 NS
Mean absolute neutrophil count among HIV+ 3689 3117 NS
ART: antiretroviral therapy; NS: not significant.
a Includes 10 samples with isoniazid mono-resistance, one sample with rifampin mono-resistance and one sample with multi-drug resistance
(both isoniazid and rifampin).
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seeking retreatment for TB, which likely contributed to underesti-
mation of MDR-TB prevalence since these individuals have the
highest risk for MDR-TB, and the sizable number of potential
patients enrolling for TB treatment that were not approached by
our study staff due to staffing shortages. Among those not
approached, there was no difference in the proportion that were
registering for first time TB treatment or retreatment, but we do
not have access to other information such as age, gender and
HIV status for further comparison. Regardless, we feel a system-
atic bias is unlikely. Prisoners were also excluded from our study
due to concerns about their ability to give consent. Given that
these individuals live in an environment known to have a higher
prevalence of MDR-TB than the general population, it is possible
that their exclusion contributed to underestimation of MDR-TB
prevalence.
Conclusions
MDR-TB prevalence is low among outpatients seeking treat-
ment in Lilongwe, emphasizing the effectiveness of Malawi’s
national TB control programme. However, future evaluation
will be necessary to identify cases of isoniazid and rifampicin
resistance in order to monitor TB control programme perform-
ance and prevent establishment of MDR-TB strains in the
country.
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